Palomino et al. (2006) was one of the first authors to study prospectively the evolution of BDNF plasma levels of patients with a final diagnosis of schizophrenia was measured at baseline at the start of their first psychotic episode (4.19 ± 2.26 ng/ml) and the following months after starting treatment (often with atypical antipsychotics), with a higher level at 6 months duration (6.53 ± 2.48 ng/ml), approaching the level of the control subjects (7.55 ± 4.31 ng/ml). Here, BDNF is linked to schizophrenia.